BioCryst Pharmaceuticals | BCRX - Cost Of Sales


BioCryst Pharmaceuticals reported $9.52M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Chugai Pharma JPY 92.79B 5.23B Mar/2026
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Incyte USD 104.5M 16.68M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novavax USD 22.1M 608K Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026